Skip to search formSkip to main contentSkip to account menu

prasugrel

A novel platelet inhibitor approved for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Prasugrel… 
National Institutes of Health

Related topics

Related topics

7 relations
CERAMIDE 6 IIprasugrel 10 MGprasugrel 10 MG Oral Tablet [Effient]prasugrel 5 MG

Narrower (3)

CS 747Effientprasugrel hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study
Background: No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in… 
Highly Cited
2016
Highly Cited
2016
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
BACKGROUND Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occlusive crises, for which… 
Highly Cited
2010
Highly Cited
2010
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual…
Highly Cited
2008
Highly Cited
2008
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting…
Review
2007
Review
2007
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of oral antiplatelet agents that includes ticlopidine… 
Highly Cited
2007
Highly Cited
2007
The Disposition of Prasugrel, a Novel Thienopyridine, in Humans
Prasugrel, a prodrug, is a novel and potent inhibitor of platelet aggregation in vivo. The metabolism of prasugrel and the… 
Highly Cited
2006
Highly Cited
2006
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
AIMS This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of… 
Highly Cited
2006
Highly Cited
2006
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
The biotransformation of prasugrel to R-138727 (2-[1-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene… 
Highly Cited
2006
Highly Cited
2006
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet…
Review
2005
Review
2005
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)